Patrick J. Stiff
Impact in
- Oncology top 0.1%
- CAR-T cell therapy research
- Hematology top 0.1%
- Hematopoietic Stem Cell Transplantation
- Acute Myeloid Leukemia Research
- Multiple Myeloma Research and Treatments
Papers in
- Hematology 129
- Hematopoietic Stem Cell Transplantation 92
- Acute Myeloid Leukemia Research 48
- Multiple Myeloma Research and Treatments 29
- Oncology 134
- CAR-T cell therapy research 39
- Co-authors
- Auayporn P. Nademanee (22 shared papers)Ivana N. Micallef (21 shared papers)John F. DiPersio (23 shared papers)Richard Thomas Maziarz (20 shared papers)Gary J Bridger (12 shared papers)Tawee Tanvetyanon (4 shared papers)John Michael McCarty (8 shared papers)Brian James Bolwell (16 shared papers)
- Journals
- Blood (78 papers)Transplantation and Cellular Therapy (69 papers)Bone Marrow Transplantation (23 papers)Journal of Clinical Oncology (18 papers)British Journal of Haematology (12 papers)
- Partner nations
- United StatesCanadaItaly
In The Last Decade
Patrick J. Stiff
278 papers receiving 20.8k citations
Patrick J. Stiff's Hit Papers
Peers
Comparison fields: 5 of 144
- Oncology 12.3k
- Hematology 5.0k
- Pathology and Forensic Medicine 4.0k
- Genetics 1.9k
- Immunology 3.2k
Countries citing papers authored by Patrick J. Stiff
This map shows the geographic impact of Patrick J. Stiff's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Patrick J. Stiff with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Patrick J. Stiff more than expected).
Fields of papers citing papers by Patrick J. Stiff
This network shows the impact of papers produced by Patrick J. Stiff. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Patrick J. Stiff. The network helps show where Patrick J. Stiff may publish in the future.
Co-authors
The 25 scholars most cited alongside Patrick J. Stiff, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 288 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma Hit paper breakdown → | 2017 | 4744 |
| 2 | Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial Hit paper breakdown → | 2018 | 1855 |
| 3 | A Controlled Trial of Fluconazole to Prevent Fungal Infections in Patients Undergoing Bone Marrow Transplantation Hit paper breakdown → | 1992 | 994 |
| 4 | Voriconazole Compared with Liposomal Amphotericin B for Empirical Antifungal Therapy in Patients with Neutropenia and Persistent Fever Hit paper breakdown → | 2002 | 805 |
| 5 | Palifermin for Oral Mucositis after Intensive Therapy for Hematologic Cancers Hit paper breakdown → | 2004 | 703 |
| 6 | Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma Hit paper breakdown → | 2009 | 654 |
| 7 | KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study Hit paper breakdown → | 2021 | 627 |
| 8 | Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial Hit paper breakdown → | 2015 | 573 |
| 9 | Phase III Prospective Randomized Double-Blind Placebo-Controlled Trial of Plerixafor Plus Granulocyte Colony-Stimulating Factor Compared With Placebo Plus Granulocyte Colony-Stimulating Factor for Autologous Stem-Cell Mobilization and Transplantation for Patients With Non-Hodgkin's Lymphoma Hit paper breakdown → | 2009 | 573 |
| 10 | A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia Hit paper breakdown → | 2013 | 525 |
| 11 | Randomized Phase Ib/II Study of Gemcitabine Plus Placebo or Vismodegib, a Hedgehog Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer Hit paper breakdown → | 2015 | 479 |
| 12 | 2013 | 270 | |
| 13 | 2020 | 263 | |
| 14 | 2017 | 258 | |
| 15 | 2010 | 256 | |
| 16 | 2012 | 249 | |
| 17 | 2006 | 233 | |
| 18 | 2014 | 220 | |
| 19 | 2019 | 215 | |
| 20 | 2007 | 206 |
About Patrick J. Stiff
Patrick J. Stiff is a scholar working on Hematology, Oncology, Pathology and Forensic Medicine, Genetics and Immunology, having authored 288 papers that have together received 21.5k indexed citations. Recurring topics across this work include Hematopoietic Stem Cell Transplantation (92 papers), Lymphoma Diagnosis and Treatment (66 papers), Acute Myeloid Leukemia Research (48 papers), CAR-T cell therapy research (39 papers), Multiple Myeloma Research and Treatments (29 papers), Chronic Lymphocytic Leukemia Research (25 papers), Immune Cell Function and Interaction (25 papers) and Acute Lymphoblastic Leukemia research (24 papers). The work is most often cited by research in Oncology (12.3k citations), Hematology (5.0k citations), Pathology and Forensic Medicine (4.0k citations), Genetics (1.9k citations) and Immunology (3.2k citations). Patrick J. Stiff has collaborated with scholars based in United States, Canada and Italy. Frequent co-authors include Auayporn P. Nademanee, Ivana N. Micallef, John F. DiPersio, Richard Thomas Maziarz, Gary J Bridger, Tawee Tanvetyanon, John Michael McCarty, Brian James Bolwell, Richard I. Fisher and Gary Calandra. Their work appears in journals such as Blood, Transplantation and Cellular Therapy, Bone Marrow Transplantation, Journal of Clinical Oncology and British Journal of Haematology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.